Mesenchymal stromal cells derived from Crohn's patients deploy indoleamine 2,3-dioxygenase-mediated immune suppression, independent of autophagy

Molecular Therapy

Volumn 23, Issue 7, 2015, Pages 1248-1261

  Chinnadurai, Raghavan ^a   Copland, Ian B ^a   Ng, Spencer ^a   Garcia, Marco ^b   Prasad, Mahadev ^a   Arafat, Dalia ^c   Gibson, Greg ^c   Kugathasan, Subra ^a   Galipeau, Jacques ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE;

ARTICLE; AUTOPHAGY; CELL VACUOLE; CONTROLLED STUDY; CROHN DISEASE; GENE; GENE EXPRESSION; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IDO GENE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; UPREGULATION; BIOSYNTHESIS; BONE MARROW CELL; CELL PROLIFERATION; COCULTURE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY;

AUTOPHAGY; BONE MARROW CELLS; CELL PROLIFERATION; COCULTURE TECHNIQUES; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES;

EID: 84934434339     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.67     Document Type: Article

References (51)

1. Le Blanc, K and Mougiakakos, D (2012). Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 12: 383-396.
2. Bernardo, ME and Fibbe, WE (2013). Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13: 392-402.
3. Murphy, MB, Moncivais, K and Caplan, AI (2013). Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 45: e54.
4. Duijvestein, M, Vos, AC, Roelofs, H, Wildenberg, ME, Wendrich, BB, Verspaget, HW et al. (2010). Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 59: 1662-1669.
5. Forbes, GM, Sturm, MJ, Leong, RW, Sparrow, MP, Segarajasingam, D, Cummins, AG et al. (2014). A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol 12: 64-71.
6. Ricart, E, Jauregui-Amezaga, A, Ordas, I, Pino, S, Ramirez, AM and Panes, J (2013). Cell therapies for IBD: what works? Curr Drug Targets 14: 1453-1459.
7. Voswinkel, J, Francois, S, Simon, JM, Benderitter, M, Gorin, NC, Mohty, M et al. (2013). Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review. Clin Rev Allergy Immunol 45: 180-192.
8. Eliopoulos, N, Stagg, J, Lejeune, L, Pommey, S and Galipeau, J (2005). Allogeneic marrow stromal cells are immune rejected by MHC class I-And class II-mismatched recipient mice. Blood 106: 4057-4065.
9. Moll, G, Alm, JJ, Davies, LC, von Bahr, L, Heldring, N, Stenbeck-Funke, L et al. (2014). Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?. Stem Cells 32: 2430-2442.
10. Francois, M and Galipeau, J (2012). New insights on translational development of mesenchymal stromal cells for suppressor therapy. J Cell Physiol 227: 3535-3538.
11. Rameshwar, P (2009). Casting doubt on the safety of 'off-The-shelf' mesenchymal stem cells for cell therapy. Mol Ther 17: 216-218.
12. Galipeau, J (2013). The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 15: 2-8.
13. Papadaki, HA, Kritikos, HD, Gemetzi, C, Koutala, H, Marsh, JC, Boumpas, DT et al. (2002). Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alphamediated effect. Blood 99: 1610-1619.
14. Ma, J, Ning, YN, Xu, M, Hou, Y, Wang, N, Hou, XY et al. (2013). Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia. Blood 122: 2074-2082.
15. Tang, Y, Ma, X, Zhang, H, Gu, Z, Hou, Y, Gilkeson, GS et al. (2012). Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Clin Dev Immunol 2012: 826182.
16. Larghero, J, Farge, D, Braccini, A, Lecourt, S, Scherberich, A, Foïs, E et al. (2008). Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 67: 443-449.
17. Bocelli-Tyndall, C, Bracci, L, Spagnoli, G, Braccini, A, Bouchenaki, M, Ceredig, R et al. (2007). Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous-And allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) 46: 403-408.
18. Bernardo, ME, Avanzini, MA, Ciccocioppo, R, Perotti, C, Cometa, AM, Moretta, A et al. (2009). Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. Cytotherapy 11: 825-836.
19. Visscher, PM, Brown, MA, McCarthy, MI and Yang, J (2012). Five years of GWAS discovery. Am J Hum Genet 90: 7-24.
20. Tardito, S, Negrini, S, Conteduca, G, Ferrera, F, Parodi, A, Battaglia, F et al. (2013). Indoleamine 2,3 dioxygenase gene polymorphisms correlate with CD8+ Treg impairment in systemic sclerosis. Hum Immunol 74: 166-169.
21. Hampe, J, Franke, A, Rosenstiel, P, Till, A, Teuber, M, Huse, K et al. (2007). A genomewide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 39: 207-211.
22. Rioux, JD, Xavier, RJ, Taylor, KD, Silverberg, MS, Goyette, P, Huett, A et al. (2007). Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 39: 596-604.
23. Lapaquette, P, Brest, P, Hofman, P and Darfeuille-Michaud, A (2012). Etiology of Crohn's disease: many roads lead to autophagy. J Mol Med (Berl) 90: 987-996.
24. Gianchecchi, E, Delfino, DV and Fierabracci, A (2014). Recent insights on the putative role of autophagy in autoimmune diseases. Autoimmun Rev 13: 231-241.
25. Nys, K, Agostinis, P and Vermeire, S (2013). Autophagy: a new target or an old strategy for the treatment of Crohn's disease?. Nat Rev Gastroenterol Hepatol 10: 395-401.
26. Plantinga, TS, Crisan, TO, Oosting, M, van de Veerdonk, FL, de Jong, DJ, Philpott, DJ et al. (2011). Crohn's disease-Associated ATG16L1 polymorphism modulates proinflammatory cytokine responses selectively upon activation of NOD2. Gut 60: 1229-1235.
27. Copland, IB, Garcia, MA, Waller, EK, Roback, JD and Galipeau, J (2013). The effect of platelet lysate fibrinogen on the functionality of MSCs in immunotherapy. Biomaterials 34: 7840-7850.
28. Chinnadurai, R, Copland, IB, Patel, SR and Galipeau, J (2014). IDO-independent suppression of T cell effector function by IFN-?-licensed human mesenchymal stromal cells. J Immunol 192: 1491-1501.
29. Nath, AP, Arafat, D and Gibson, G (2012). Using blood informative transcripts in geographical genomics: impact of lifestyle on gene expression in fijians. Front Genet 3: 243.
30. Krampera, M, Galipeau, J, Shi, Y, Tarte, K and Sensebe, L; MSC Committee of the International Society for Cellular Therapy (ISCT) (2013). Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15: 1054-1061.
31. Ren, G, Zhang, L, Zhao, X, Xu, G, Zhang, Y, Roberts, AI et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2: 141-150.
32. Powell, DW, Pinchuk, IV, Saada, JI, Chen, X and Mifflin, RC (2011). Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol 73: 213-237.
33. Armaka, M, Apostolaki, M, Jacques, P, Kontoyiannis, DL, Elewaut, D and Kollias, G (2008). Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 205: 331-337.
34. Dominici, M, Le Blanc, K, Mueller, I, Slaper-Cortenbach, I, Marini, F, Krause, D et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
35. Horwitz, EM, Le Blanc, K, Dominici, M, Mueller, I, Slaper-Cortenbach, I, Marini, FC et al.; International Society for Cellular Therapy. (2005). Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7: 393-395.
36. Romieu-Mourez, R, Francois, M, Boivin, MN, Stagg, J and Galipeau, J (2007). Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol 179: 1549-1558.
37. Francois, M, Romieu-Mourez, R, Li, M and Galipeau, J (2012). Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20: 187-195.
38. Zenewicz, LA, Antov, A and Flavell, RA (2009). CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 15: 199-207.
39. Romieu-Mourez, R, Coutu, DL and Galipeau, J (2012). The immune plasticity of mesenchymal stromal cells from mice and men: concordances and discrepancies. Front Biosci (Elite Ed) 4: 824-837.
40. Ren, J, Jin, P, Sabatino, M, Balakumaran, A, Feng, J, Kuznetsov, SA et al. (2011). Global transcriptome analysis of human bone marrow stromal cells (BMSC) reveals proliferative, mobile and interactive cells that produce abundant extracellular matrix proteins, some of which may affect BMSC potency. Cytotherapy 13: 661-674.
41. Rafei, M, Hsieh, J, Fortier, S, Li, M, Yuan, S, Birman, E et al. (2008). Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 112: 4991-4998.
42. Cox, JH, Dean, RA, Roberts, CR and Overall, CM (2008). Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding. J Biol Chem 283: 19389-19399.
43. Schroepf, S, Kappler, R, Brand, S, Prell, C, Lohse, P, Glas, J et al. (2010). Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis 16: 1882-1890.
44. Chinnadurai, R, Waller, EK, Galipeau, J and Nooka, AK (2013). From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases. Biomed Res Int 2013: 929842.
45. Saitoh, T, Fujita, N, Jang, MH, Uematsu, S, Yang, BG, Satoh, T et al. (2008). Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456: 264-268.
46. Cadwell, K, Liu, JY, Brown, SL, Miyoshi, H, Loh, J, Lennerz, JK et al. (2008). A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456: 259-263.
47. Murthy, A, Li, Y, Peng, I, Reichelt, M, Katakam, AK, Noubade, R et al. (2014). A Crohn's disease variant in Atg16l1 enhances its degradation by caspase 3. Nature 506: 456-462.
48. Lassen, KG, Kuballa, P, Conway, KL, Patel, KK, Becker, CE, Peloquin, JM et al. (2014). Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Proc Natl Acad Sci U S A 111: 7741-7746.
49. Fujita, N, Saitoh, T, Kageyama, S, Akira, S, Noda, T and Yoshimori, T (2009). Differential involvement of Atg16L1 in Crohn disease and canonical autophagy: analysis of the organization of the Atg16L1 complex in fibroblasts. J Biol Chem 284: 32602-32609.
50. Chinnadurai, R, Garcia, MA, Sakurai, Y, Lam, WA, Kirk, AD, Galipeau, J et al. (2014). Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo. Stem Cell Reports 3: 60-72.
51. Francois, M, Copland, IB, Yuan, S, Romieu-Mourez, R, Waller, EK and Galipeau, J (2012). Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-licensing. Cytotherapy 14: 147-152.